Clinical trial
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)
ClinicalTrials.gov ID: NCT02003924
Sponsor: Pfizer
Information provided by: Pfizer (Responsible Party)
Last Update Posted: 2023-10-10
Brief Summary:
The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
Official Title:
PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Intervention / Treatment:
- Drug: Enzalutamide
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) |
2013-10-31
|
| Primary Completion (Actual) |
2017-06-28
|
| Study Completion (Estimated) |
2023-12-29
|
| Enrollment (Actual) | 1401 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
MDV3100-14
C3431005 (Other Identifier) (OTHER: Alias Study Number) 2012-005665-12 (EudraCT Number) |